Sean McCoy, Solution Manger at CBT, will discuss with Novartis’ Szczepan Baran, Head of Emerging Technology, on the importance of creating a holistic solution when implementing a connected worker environment. You will hear first-hand experiences from a customer and supplier as they discuss the best practices through the sales cycle, implementation cycle and then the adoption cycle.
Sean McCoy joined CBT as a Solutions Manager – Worker Safety & Security in 2021. CBT applies their expertise in integration at the point where IT and OT converge leading to sustainable and real business transformation. After graduating high school Sean spent 6 years in the United States Navy as an Electronics Technician with 4 of those years on the USS Rushmore (LSD-47). Since his honorable discharge in 1998 he spent over 18 years in oil and gas serving in various roles and companies in manufacturing, sales, business development and marketing with 9 of those years at Schlumberger. In 2017 he had the chance to pursue the entrepreneurial dream creating and running his own business, a for profit social enterprise, that designed a custom-made mobile application with Artificial Intelligence as the basis for its operations that linked consumers, businesses and non-profit organizations for the economic and social benefit of all three. Sean is also a professional podcaster with the Oil & Gas Global Network where he currently is the co-host of Oil & Gas Elevate which is a weekly show focused on ESG and the Energy Evolution. He’s a dedicated husband, father and friend. His favorite hobbies are mountain biking, sporting clays and snorkeling. He received his BS in Interdisciplinary Studies with a minor in History from the University of Houston-Downton graduating with honors in 2004. Sean is available to talk to you about making the impossible, possible for your business through technology adoption and implementation. You can reach him at email@example.com
Szczepan Baran, is a scientist and comparative medicine veterinarian turned “technology geek.” He is passionate about transforming the delivery of innovative medicines to patients through digital technologies and data enablement to be more efficient, cost-effective, and environmentally conscious while pushing the scientific envelope and reimagining patient engagement. Szczepan currently heads the Global Emerging Technologies (GET) within Comparative Medicine at Novartis. In this position, he leads an integrated digital enterprise strategy to modernize and increase the agility of current processes, with a current focus on the development and incorporation of patient-relevant AI technologies and digital endpoints. In parallel, Szczepan focuses on stakeholder engagement to identify adaptation hurdles and develop regulatory qualification pathways for Microphysiological Systems (MPS) technologies. Szczepan has played instrumental roles in establishing and leading the Global Novartis Institutes for BioMedical Research (NIBR) Preclinical Digital Biomarkers and MPS Groups with a vision for strategic alignment and data agility. Szczepan is a graduate of the University of Delaware and the University of Pennsylvania School of Veterinary Medicine. He completed his residency in Laboratory Animal Medicine and received a Master of Science degree in Comparative Medicine from the University of Washington School of Medicine. Szczepan began his career at the Fred Hutchinson Cancer Research Center, where he was recruited to develop the first canine embryonic stem cell lines and collaborate on developing novel canine transplantation protocols to eliminate graft-versus-host disease. Before joining Novartis, Szczepan held multiple start-up and faculty positions and served on numerous boards. Currently, he serves as a chair of the Translational Biomarker Initiative of the North American 3Rs Collaborative. He is a vice-chair of the IQ Microphysiological Systems (MPS) Affiliate and leads the IQ MPS Affiliate Regulatory Outreach Group. He is a Medical & Scientific Advisory Board member at the Canines-N-Kids Foundation. He serves as a Scientific Advisory Committee on Alternative Toxicological Methods (SACATM) ad hoc member, AAALAC ad hoc specialist, and the Boston Innovation Advisory Council member.